Platelet thromboxane A2/prostaglandin H2 receptors in human volunteers on low doses of aspirin

Biochem Pharmacol. 1990 Oct 1;40(7):1559-61. doi: 10.1016/0006-2952(90)90454-s.

Abstract

Administration of aspirin (81 mg/day for 2-3 weeks) in nine healthy volunteers (out of an initial ten subjects, only nine qualified) resulted in a greater than 95% decrease of thromboxane B2 production by thrombin-stimulated platelets. At the same time, ligand binding studies with a thromboxane A2 antagonist, 125I-PTA-OH, measurements of shape change, and aggregation of platelets stimulated with U46619, a prostaglandin H2 analogue, indicated that administration of aspirin to normal human subjects does not result in the up-regulation of platelet thromboxane A2/prostaglandin H2 receptors.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adult
  • Aspirin / administration & dosage
  • Aspirin / pharmacology*
  • Blood Platelets / drug effects*
  • Blood Platelets / metabolism
  • Female
  • Humans
  • Male
  • Platelet Aggregation / drug effects
  • Prostaglandin Endoperoxides, Synthetic / pharmacology
  • Receptors, Prostaglandin / metabolism*
  • Receptors, Thromboxane
  • Receptors, Thromboxane A2, Prostaglandin H2
  • Thrombin
  • Thromboxane A2 / analogs & derivatives
  • Thromboxane A2 / antagonists & inhibitors
  • Thromboxane A2 / pharmacology
  • Thromboxane B2 / metabolism

Substances

  • Prostaglandin Endoperoxides, Synthetic
  • Receptors, Prostaglandin
  • Receptors, Thromboxane
  • Receptors, Thromboxane A2, Prostaglandin H2
  • Thromboxane B2
  • Thromboxane A2
  • I-PTA-OH
  • Thrombin
  • Aspirin